1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

Drop biologic suffixes IGBA urges US FDA

Additional identifiers such as suffixes to international non-proprietary names (INNs) are not needed for successful traceability and identification of biological drugs, the International Generic and Biosimilar Medicines Association (IGBA) argues in an updated position. “No data exists to demonstrate that added non-memorable suffixes in the US will improve the US pharmacovigilance system,” the international trade body has stressed ahead of a US Food and Drug Administration (FDA) public hearing on “facilitating price competition and innovation in the biological products marketplace” to be held on 4 September (Generics bulletin, 3 August 2018, page 9).

Additional identifiers such as suffixes to international non-proprietary names (INNs) are not needed for successful traceability and identification of biological drugs, the International Generic and Biosimilar Medicines Association (IGBA) argues in an updated position. “No data exists to demonstrate that added non-memorable suffixes in the US will improve the US pharmacovigilance system,” the international trade body has stressed ahead of a US Food and Drug Administration (FDA) public hearing on “facilitating price competition and innovation in the biological products marketplace” to be held on 4 September (Generics bulletin, 3 August 2018, page 9).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

OGD’s Policy Office Cut To Have ‘Profound’ Impact On New Generic Approvals, Warns Former FDA Head Gottlieb

 
• By Urtė Fultinavičiūtė

The elimination of the policy division at the Office of Generic Drugs, tariffs, the Section 232 investigation, and a new executive order to promote lower drug prices seem to both cause and purport to solve the same problem: supply chain disruption.

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

More from Policy & Regulation

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

Regulatory Recap: UK To Capture £1bn Savings With Framework For Best-Value Biologics

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.

As US Launches Pharma Probe, AAM Warns Tariffs ‘Will Only Amplify Problems’

 
• By Dave Wallace

News of a fresh US investigation into the pharma sector has sparked renewed concerns over the impact that US trade tariffs would have on the generics and biosimilars industry. The AAM has responded with a warning over the potential effects on shortages and access, while Medicines for Europe has proposed five key action areas to bolster the sector in Europe.